Conference abstractPublished 7 Nov 2016

A regulatory update on the US generic drug review and approval process following the implementation of 2012 generic drug user fee law

Authors: Duu Gong Wu

PPD Regulatory Consulting, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

It has been three years since the implementation of Generic Drug User Fee Amendment in US. Significant changes associated with a complete Over Half of generic drug review and approval process has since been implemented. Meanwhile, FDA has published many guidance documents to deal with filing and review procedures, organization of ANDA submission, and scientific requirements such as those for stability and impurities. At the same time, the formation of Office of Pharmaceutical Quality (OPQ) combined the quality reviews of new drugs, biotechnology products and generic drugs (Life Cycle Products) under a single organization and incorporated the manufacturing sciences and product surveillance into the review system. These changes under the concept of risk-based CMC reviews and GMP inspections and life cycle management present certain challenges to a generic drug company which plans to enter US generic market. The presentation will detail the changes implemented in the last three years and discuss their implications and common issues regarding how to prepare a good ANDA application.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Duu Gong Wu”